Eli Lilly Downgraded To Neutral From Buy At Goldman Sachs
January 16, 2018 at 05:46 AM EST
Goldman Sachs analyst Jami Rubin downgraded Eli Lilly to Neutral and cut her price target for the shares to $95 from $98.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|